Pharma channel feed

Pfiz­er's Q4 rev­enue tum­bles 42% amid Covid re­set

Last year

Gilead in­vests an­oth­er $320M in Ar­cus as part­ners re­hash their TIG­IT pact

Last year
Deals
R&D

Ju­ry awards Nat­era $96M+ in blood test patent fight

Last year
Law

GSK shoots for RSV la­bel ex­pan­sion in younger adults in Eu­rope in race against Pfiz­er’s Abrys­vo

Last year
FDA+

Bris­tol My­er­s' Op­di­vo fails part two of post-kid­ney can­cer surgery test as com­peti­tor Mer­ck touts new sur­vival da­ta

Last year
R&D

Two new drugs get pos­i­tive rec­om­men­da­tions from EMA com­mit­tee, while two oth­ers get thumbs-down

Last year
FDA+

Com­pe­ti­tion en­force­ment led to fair­er prices, in­no­v­a­tive prod­ucts — EC re­port

Last year
FDA+

Check your dad jeans — and genes — in J&J's new BR­CA-fo­cused cam­paign

Last year
Marketing

Sen­ate Fi­nance Com­mit­tee plots ways to tweak Medicare to re­duce ster­ile in­jectable short­ages

Last year

As PBMs face threats in Wash­ing­ton, in­dus­try trade group poured mil­lions more in­to lob­by­ing

Last year
FDA+

‘I think we will have the votes’: Sanders gears up to sub­poe­na CEOs of J&J, Mer­ck to tes­ti­fy on drug prices

Last year
FDA+

Bris­tol My­ers de­buts first TV ad for heart con­di­tion drug Camzyos

Last year
Marketing

Gener­ic in­dus­try group sues Illi­nois over drug price law

Last year
Law

J&J con­tin­ues build­ing out pso­ri­a­sis im­age li­brary with di­verse skin types

Last year
Marketing

Roche and Ex­elix­is de­tail rare suc­cess for Cabome­tyx-Tecen­triq com­bo in prostate can­cer

Last year
R&D

Fol­low­ing CAR-T safe­ty la­bel changes, FDA of­fi­cials share new de­tails about sec­ondary can­cer cas­es

Last year
Cell/Gene Tx
FDA+

Au­vi-q al­ler­gy in­jec­tor re­cruits Brit­tany Ma­homes for new cam­paign

Last year
Marketing

On­col­o­gists want more treat­ment op­tions for ad­vanced lung can­cer pa­tients, new sur­vey says

Last year
Marketing

Dan­co to SCO­TUS: Abor­tion pill re­stric­tions could 'desta­bi­lize the phar­ma­ceu­ti­cal in­dus­try'

Last year
Law

FDA up­dates Gilead­'s la­bel for CAR-T Tecar­tus with new boxed warn­ing for sec­ondary can­cer

Last year
Cell/Gene Tx
FDA+

Up­dat­ed: Gilead’s Tecar­tus dropped from list of CAR-Ts with up­dat­ed boxed warn­ings

Last year
Cell/Gene Tx
FDA+

Talc mar­ket­ing claims against J&J close to po­ten­tial set­tle­ment with 40+ states

Last year
Law

Gilead clos­es $247M HIV drug set­tle­ment deal

Last year
Law

J&J talks up $3B in deals that did­n't make head­lines in 2023

Last year
Deals
First page Previous page 77787980818283 Next page Last page
A service from the Financial Times